Alkem Laboratories
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Alkem Laboratories is strategically enhancing its growth trajectory through international expansion and investments in high-growth sectors like biosimilars and MedTech. Management's optimism is supported by a record EBITDA performance and successful product launches, particularly in the chronic segment, which is expected to drive revenue growth. However, the company faces execution risks and margin pressures due to rising operational costs and regulatory challenges. Vista's financial outlook reflects stable revenue growth, albeit with anticipated margin pressures, as the company navigates a complex cost environment. The expected upside remains modest, with a target price of INR 6,190 over the next 12 months. Industry dynamics, including improving pricing power and a favorable regulatory environment, provide a supportive backdrop for Alkem's growth, despite potential headwinds from inflation and geopolitical factors. Over the next 12-24 months, key opportunities include the commissioning of a US biomanufacturing facility and new product launches, while watchpoints include execution risks and cost pressures that could impact margins
Why We Like This Stock
- Successful product launches, particularly in the chronic segment, are expected to drive revenue growth
- Strategic acquisitions and investments in high-growth areas like biosimilars and MedTech enhance long-term growth prospects
- Management's focus on supply chain resilience and operational stability supports a positive outlook
Things To Watch Out For
- Rising operational costs and regulatory challenges are expected to exert pressure on margins
- Execution risks related to client acquisition and capacity expansion could hinder growth
- Geopolitical factors may lead to increased logistics and API costs, impacting profitability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 12,668 | 12,965 | 14,712 | 15,250 | 17,264 |
| Profit Before Tax (Cr.) | 2,148 | 2,522 | 3,046 | 3,019 | 3,501 |
| PBT Margin | 17.0% | 19.5% | 2070.4% | 19.8% | 20.3% |
| Net Profit (Cr.) | 1,699 | 1,998 | 2,386 | 2,368 | 2,690 |
| Earnings Per Share | 140.8 | 163.0 | 195.5 | 194.0 | 225.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ► Hold | 5,775 | 29-May-2026 |
| HDFC Securities | ► Add | 6,230 | 29-May-2026 |
| ICICI Securities | ▲ Buy | 6,850 | 29-May-2026 |
| Investec | ▲ Buy | 6,500 | 17-Aug-2026 |
| JPMorgan | ► Hold | 6,100 | 17-Aug-2026 |
| Jeffries | ▲ Buy | 6,500 | 29-May-2026 |
| Macguire | ▼ Underperform | 4,900 | 17-Aug-2026 |
| Motilal Oswal | ► Neutral | 5,840 | 29-May-2026 |
| Nomura | ▲ Buy | 6,890 | 29-May-2026 |
Company Overview
Show Company Profile
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.